2. Signaling Pathways
  3. Immunology/Inflammation
  4. Kallikrein

Kallikrein

KLK; Kallikrein-related peptidase

 

Kallikrein Isoform Specific Products:

Kallikrein Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16735
    Avoralstat
    		Inhibitor ≥98.0%
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.
    Avoralstat
  • HY-109127A
    Berotralstat dihydrochloride
    		Inhibitor 98.49%
    Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.
    Berotralstat dihydrochloride
  • HY-132830
    Sebetralstat
    		Inhibitor 99.58%
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
    Sebetralstat
  • HY-P99110
    Lanadelumab
    		Inhibitor
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.
    Lanadelumab
  • HY-109127
    Berotralstat
    		Inhibitor 99.70%
    Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
    Berotralstat
  • HY-123133
    PKSI-527
    		Inhibitor 98.08%
    PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.
    PKSI-527
  • HY-148949
    Kallikrein 5-IN-2
    		98.69%
    Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching.
    Kallikrein 5-IN-2
  • HY-P0237A
    KKI-5 TFA
    		98.74%
    KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.
    KKI-5 TFA
  • HY-108814A
    Ecallantide TFA
    		Inhibitor 98.63%
    Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.
    Ecallantide TFA
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone
    		Inhibitor 98.95%
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
    D-Pro-Phe-Arg-Chloromethylketone
  • HY-145568
    Feniralstat
    		Inhibitor 99.87%
    Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
    Feniralstat
  • HY-122543
    PPACK II diTFA
    		Inhibitor
    PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.
    PPACK II diTFA
  • HY-126378
    LSP-249
    		Inhibitor 99.05%
    LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell.
    LSP-249
  • HY-148949A
    Kallikrein 5-IN-2 TFA
    		Inhibitor
    Kallikrein 5-IN-2 TFA is the TFA salt form of Kallikrein 5-IN-2 (HY-148949). Kallikrein 5-IN-2 TFA is a selective inhibitor for kallikrein 5 (KLK5) with pIC50 of 7.1. Kallikrein 5-IN-2 TFA is non-phototoxic (100 μg/mL) and non-irritant. Kallikrein 5-IN-2 is stable at pH 4-pH 8 under non-oxidative condition. Kallikrein 5-IN-2 is potent in ameliorating the Netherton syndrome.
    Kallikrein 5-IN-2 TFA
  • HY-153115
    Plasma kallikrein-IN-4
    		Inhibitor 98.61%
    Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein.
    Plasma kallikrein-IN-4
  • HY-139888
    Plasma kallikrein-IN-1
    		Inhibitor
    Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.
    Plasma kallikrein-IN-1
  • HY-114150D
    D-Val-Leu-Arg-pNA acetate
    D-Val-Leu-Arg-pNA (acetate) is the acetate form of D-Pro-Phe-Arg-p-nitroanilide (pNa). D-Pro-Phe-Arg-p-nitroanilide (pNa) is the substrate for kallikrein and can be used to assay the activity of kallikrein.
    D-Val-Leu-Arg-pNA acetate
  • HY-108814
    Ecallantide
    		Inhibitor
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
    Ecallantide
  • HY-122543A
    PPACK II
    		Inhibitor
    PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor.
    PPACK II
  • HY-143476
    Plasma kallikrein-IN-2
    		Inhibitor
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-2
Cat. No. Product Name / Synonyms Application Reactivity
Kallikrein Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.